Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

First report to study clonal population of maxillary sinus carcinoma

Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published today by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

The Coalition for Pulmonary Fibrosis (CPF) proudly announces the winners of its three annual awards for distinguished service. Each honoree has made vital contributions to the effort to fight Pulmonary Fibrosis (PF) – in research, humanitarian and advocacy efforts.

28 Sep 2012

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.

27 Sep 2012

CTCA at Midwestern named Certified Quality Breast Center of Excellence

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) has been recognized by the National Quality Measures for Breast Centers Program (NQMBC) as being among the top centers in the country for providing quality breast cancer care.

27 Sep 2012

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.

26 Sep 2012

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

UC Davis cancer researchers have discovered significant differences in radiation-therapy response among patients with oropharyngeal cancer depending on whether they carry the human papillomavirus (HPV), a common sexually transmitted virus. The findings, published online today in The Laryngoscope Journal, could lead to more individualized radiation treatment regimens, which for many patients with HPV could be shorter and potentially less toxic.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

ProMedica invests $710,000 in new cancer and infusion center in Fostoria, Ohio

Cancer patients in Fostoria, Ohio, now have access to advanced cancer treatment and protocols close to home. The ProMedica Cancer Institute has invested $710,000 in a new cancer and infusion center in Fostoria, Ohio. The rural community has a population of 13,000 residents.

25 Sep 2012

NVIDIA video cards can help reduce radiation exposure from X-ray and CT scans

Video gamers are generally the biggest consumers of computer graphics cards, using the devices to boost the speed and resolution of their digital quests to fend off invading extraterrestrials or outwit hostile dragons. But researchers at Rensselaer Polytechnic Institute seek to harness the power of these computer graphics cards to solve one of the world's most pressing health care technology challenges: radiation exposure from X-ray and CT imaging scans.

25 Sep 2012

ASTRO's Annual Meeting to be held in Boston from Oct. 28-31

ASTRO's Annual Meeting is the premier scientific meeting in radiation oncology and is expected to attract more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants, practice administrators, industry representatives and other health care professionals from around the world.

24 Sep 2012

UK scientists make breakthrough in new method of brain tumour diagnosis

UK scientists have made a breakthrough in a new method of brain tumour diagnosis, offering hope to tens of thousands of people.

20 Sep 2012

Harris Health System celebrates completion of Smith Clinic

On Sept. 12, Harris Health System celebrated the completion of Smith Clinic, the system's first outpatient specialty facility. The new facility enhances and expands specialty care for patients formerly seen at hospital-based clinics located at Ben Taub Hospital.

18 Sep 2012

University of Central Florida professor receives NIH’s New Innovator award

The National Institutes of Health today awarded University of Central Florida Professor Ming Su its coveted New Innovator award, which comes with a $2 million grant.

14 Sep 2012

FDG–PET/CT improves staging and modifies radiotherapy management

The addition of FDG–positron emission tomography/computed tomography revised radiotherapy decision-making and enhanced tumor staging capabilities in patients with non-small-cell lung cancer, research shows.

13 Sep 2012

Four new studies on the treatment of early breast cancer

Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium.

13 Sep 2012

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

New evidence that women are more likely to be harmed than helped by screening tests for ovarian cancer is disturbing. The tests do nothing to prevent healthy women from dying from the usually fatal disease. Yet they often lead doctors to perform needless surgeries that cause serious complications in many patients.

13 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

Mammalian target of rapamycin inhibitors can prevent radiation-induced tissue damage

Radiation therapy is one of the most widely used cancer treatments, but it often damages normal tissue and can lead to debilitating conditions. A class of drugs known as mammalian target of rapamycin (mTOR) inhibitors can prevent radiation-induced tissue damage in mice by protecting normal stem cells that are crucial for tissue repair, according to a preclinical study published by Cell Press in the September issue of the journal Cell Stem Cell.

7 Sep 2012

Radiation Therapy News and Research

Further Reading

First report to study clonal population of maxillary sinus carcinoma

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

CTCA at Midwestern named Certified Quality Breast Center of Excellence

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

ProMedica invests $710,000 in new cancer and infusion center in Fostoria, Ohio

NVIDIA video cards can help reduce radiation exposure from X-ray and CT scans

ASTRO's Annual Meeting to be held in Boston from Oct. 28-31

UK scientists make breakthrough in new method of brain tumour diagnosis

Harris Health System celebrates completion of Smith Clinic

University of Central Florida professor receives NIH’s New Innovator award

FDG–PET/CT improves staging and modifies radiotherapy management

Four new studies on the treatment of early breast cancer

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Mammalian target of rapamycin inhibitors can prevent radiation-induced tissue damage

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News